Comparison of the efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis

dc.contributor.authorTikiz C.
dc.contributor.authorÜnlü Z.
dc.contributor.authorŞener A.
dc.contributor.authorEfe M.
dc.contributor.authorTüzün C.
dc.date.accessioned2024-07-22T08:23:50Z
dc.date.available2024-07-22T08:23:50Z
dc.date.issued2005
dc.description.abstractWe aimed to compare the efficacy of intra-articular injections of a lower molecular weight hyaluronan (LMW HA) (Ostenil) with a higher molecular weight viscosupplement (hylan G-F 20, Synvisc) in hip osteoarthritis. For this purpose, 43 patients (56 hips) with hip osteoarthritis with a visual analogue scale (VAS) pain score higher than 50/100, a Lequesne index greater than 6, and persistence of the pain for longer than 3 months despite all conservative methods were enrolled in the study and randomly assigned to two groups: 25 (32 hips) received LMW HA and the remaining 18 patients (24 hips) received hylan G-F 20. Three injections were administered once weekly to each patient under fluoroscopic guidance. During the 6-month follow-up period, the primary outcomes were assessed at the 1st, 3rd, and 6th month by VAS, WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index), and Lequesne index. The intra-articular injections produced a significant reduction in VAS, WOMAC, and Lequesne index scores in both groups. After three injections, improvement was prominent at the 1st month and maintained for 6 months in both groups. The percentage reduction was 38 and 40% (p<0.001) in VAS pain score, 43 and 40% in WOMAC (p<0.001), and 47 and 49% in Lequesne index (p<0.001) in the LMW HA and hylan G-F groups at the 6th month, respectively. However, there were no significant differences in outcomes between any of the measurements at the 1st, 3rd, and 6th month between the two groups (p>0.05). No systemic adverse effect was recorded. Local adverse effects consisting of pain and/or swelling were noted in 3 of 32 hips (9%) injected with LMW HA and in 3 of 24 hips (12.5%) injected with hylan G-F 20. In conclusion, both types of viscosupplementation produced a significant clinical improvement during the 6-month follow-up period. However, no significant difference was found in outcomes between higher and lower molecular weight hyaluronan. © Clinical Rheumatology 2005.
dc.identifier.DOI-ID10.1007/s10067-004-1013-5
dc.identifier.issn07703198
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19710
dc.language.isoEnglish
dc.subjectAdjuvants, Immunologic
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectDisease Progression
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectHyaluronic Acid
dc.subjectInjections, Intra-Articular
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectOsteoarthritis, Hip
dc.subjectProspective Studies
dc.subjectSingle-Blind Method
dc.subjectTreatment Outcome
dc.subjectanalgesic agent
dc.subjecthigh molecular weight hyaluronic acid
dc.subjecthyaluronic acid
dc.subjecthylan g f 20
dc.subjectlow molecular weight hyaluronic acid
dc.subjectnonsteroid antiinflammatory agent
dc.subjectostenil
dc.subjectunclassified drug
dc.subjectadult
dc.subjectaged
dc.subjectarthralgia
dc.subjectarticle
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectcomparative study
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdrug efficacy
dc.subjectdrug intermittent therapy
dc.subjectdrug response
dc.subjectdrug tolerability
dc.subjectfemale
dc.subjectfluoroscopy
dc.subjectfollow up
dc.subjectgeneral condition improvement
dc.subjecthip osteoarthritis
dc.subjecthuman
dc.subjectinflammation
dc.subjectmale
dc.subjectpain
dc.subjectpain assessment
dc.subjectphysiotherapy
dc.subjectpriority journal
dc.subjectrandomized controlled trial
dc.subjectscoring system
dc.subjectsingle blind procedure
dc.subjectvisual analog scale
dc.titleComparison of the efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis
dc.typeArticle

Files